Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

454 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia.
Kadia TM, Yang H, Ferrajoli A, Maddipotti S, Schroeder C, Madden TL, Holleran JL, Egorin MJ, Ravandi F, Thomas DA, Newsome W, Sanchez-Gonzalez B, Zwiebel JA, Espinoza-Delgado I, Kantarjian HM, Garcia-Manero G. Kadia TM, et al. Br J Haematol. 2010 Jul;150(1):72-82. doi: 10.1111/j.1365-2141.2010.08211.x. Epub 2010 Apr 29. Br J Haematol. 2010. PMID: 20456355 Free PMC article. Clinical Trial.
Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation.
Chen Y, Cortes J, Estrov Z, Faderl S, Qiao W, Abruzzo L, Garcia-Manero G, Pierce S, Huang X, Kebriaei P, Kadia T, De Lima M, Kantarjian H, Ravandi F. Chen Y, et al. Among authors: kadia t. J Clin Oncol. 2011 Jun 20;29(18):2507-13. doi: 10.1200/JCO.2010.34.2873. Epub 2011 May 9. J Clin Oncol. 2011. PMID: 21555694 Free PMC article. Clinical Trial.
Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Kantarjian H, O'Brien S, Jabbour E, Shan J, Ravandi F, Kadia T, Faderl S, Garcia-Manero G, Borthakur G, Cortes J. Kantarjian H, et al. Among authors: kadia t. J Clin Oncol. 2011 Aug 10;29(23):3173-8. doi: 10.1200/JCO.2010.33.4169. Epub 2011 Jul 11. J Clin Oncol. 2011. PMID: 21747082 Free PMC article.
Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience.
Kantarjian H, O'Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, Rios MB, Ravandi F, Faderl S, Kadia T, Borthakur G, Huang X, Champlin R, Talpaz M, Cortes J. Kantarjian H, et al. Among authors: kadia t. Blood. 2012 Mar 1;119(9):1981-7. doi: 10.1182/blood-2011-08-358135. Epub 2012 Jan 6. Blood. 2012. PMID: 22228624 Free PMC article.
Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system.
Tong WG, Quintás-Cardama A, Kadia T, Borthakur G, Jabbour E, Ravandi F, Faderl S, Wierda W, Pierce S, Shan J, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Tong WG, et al. Among authors: kadia t. Cancer. 2012 Sep 15;118(18):4462-70. doi: 10.1002/cncr.27420. Epub 2012 Jan 17. Cancer. 2012. PMID: 22252728 Free PMC article.
Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.
Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HM. Faderl S, et al. Among authors: kadia t. Cancer. 2012 Sep 15;118(18):4471-7. doi: 10.1002/cncr.27429. Epub 2012 Jan 26. Cancer. 2012. PMID: 22282348 Free PMC article. Clinical Trial.
454 results